Zyner, Katherine G. http://orcid.org/0000-0002-4997-0150
Simeone, Angela
Flynn, Sean M. http://orcid.org/0000-0001-7326-2659
Doyle, Colm
Marsico, Giovanni
Adhikari, Santosh http://orcid.org/0000-0002-1501-2106
Portella, Guillem
Tannahill, David http://orcid.org/0000-0002-3811-6864
Balasubramanian, Shankar http://orcid.org/0000-0002-0281-5815
Funding for this research was provided by:
Cancer Research UK (C9545/A19836, C9681/A29214, C9545/A19836, C9681/A29214, C9545/A19836, C9681/A29214, C9545/A19836, C9681/A29214, C9545/A19836, C9681/A29214, C9545/A19836, C9681/A29214, C9545/A19836, C9545/A19836, C9545/A19836, C9681/A29214)
Leverhulme Trust (ECF-2021-398)
Wellcome Trust (209441/Z/17/Z)
Herchel Smith Funds
Article History
Received: 5 February 2021
Accepted: 2 December 2021
First Online: 10 January 2022
Competing interests
: S.B. is a founder and shareholder of Cambridge Epigenetix Ltd. All other authors declare no competing interests.